Structured page family:Cost guide
Linaclotide Cost Guide: Insurance, Cash Pay, and Savings
In the United States, Linaclotide costs depend on brand, pharmacy, insurance design, and whether the patient qualifies for manufacturer savings programs.
Active Market
This page is designed for US treatment decisions and uses US-first pricing and savings sources.
Official pricing
Verify current pricing directly on official Linzess pages before starting, because list pricing, self-pay offers, and eligibility terms can change.
Cash-pay reality
Official cash-pay pricing varies by pharmacy and dose. Contact multiple pharmacies or use a prescription discount service for current rates.
Insurance coverage
Commercial coverage for Linaclotide varies by plan and indication. Prior authorization is commonly required.
Savings and coupons
Manufacturer savings programs may reduce out-of-pocket cost for eligible commercially insured patients.
Prior Authorization
Prior authorization is common and may require documentation of diagnosis, prior treatments, and clinical need.
Price Breakdown
List price (monthly)
~$400-$500/month
Average wholesale price
~$380-$480/month
Pharmacy acquisition estimate
~$350-$450/month
Typical negotiated rate
~$250-$350/month
Price per dose
~$13 per 145 mcg; ~$17 per 290 mcg
Annual cost at list price
~$4,800-$6,000
Pharmacy Price Comparison
| Pharmacy | Price Range | Notes |
|---|---|---|
| Retail | $380-$500/month | Brand pricing |
| GoodRx | $300-$450/month | Discounted |
| Costco | $350-$480/month | Slight discount |
Insurance Coverage Landscape
Commercial plans
~70-80% after step therapy
Medicare Part D
Covered
Medicaid
Most states cover with prior auth
VA coverage
On formulary
TRICARE
Covered
Employer plan typical tier
Tier 2-3; copay $30-75
Prior Authorization Guide
Required Documentation
- •IBS-C or CIC diagnosis
- •Failed fiber supplements
- •Failed osmotic laxative (PEG)
- •Failed lubiprostone (sometimes required)
Common Denial Reasons
- •Step therapy not completed
- •OTC alternatives not tried
- •Diagnosis not confirmed
Appeal Template Points
- •FDA-approved for IBS-C/CIC
- •Failed conservative measures
- •Significant quality of life impact
- •Guideline-concordant
Expected timeline: 3-5 days
Savings Programs and Patient Assistance
Linzess Savings Card
copayEligibility: Commercially insured
Savings: $30/month
Income limit: None
Enrollment: simple
AbbVie program
AbbVie PAP
manufacturerEligibility: Uninsured, ≤400% FPL
Savings: Free
Income limit: ≤400% FPL
Enrollment: moderate
Annual application
Generic and Biosimilar Status
No generic currently available
Expected: Generic expected late 2020s
Cost by Dose
| Dose/Regimen | Monthly | Annual |
|---|---|---|
| 72 mcg (CIC lowest) | $400 | $4,800 |
| 145 mcg (CIC standard) | $400 | $4,800 |
| 290 mcg (IBS-C) | $500 | $6,000 |
Annual Cost Projection
Year 1
$360-$6,000
Year 2
$360-$6,000
Year 3
$360-$6,000 (generic may emerge)
Assumptions
- •Brand pricing until generic
- •Insurance coverage
Cost-Saving Strategies
- 1.Linzess savings card reduces copay to $30
- 2.Start with lowest effective dose for CIC (72-145 mcg)
- 3.Ensure step therapy documented (fiber, PEG failed)
- 4.GoodRx may beat insurance on cash price
International Price Comparison
| Country | Price Range | Notes |
|---|---|---|
| UK | ~£80-120/month (~$100-150) | NHS |
| Canada | ~CAD $300-400 (~$220-300) | Regulated |
Need help comparing linaclotide paths?
Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.
Find a linaclotide providerNext Step
Use the cost calculator
Use provider matching when you need help comparing insured and self-pay treatment paths.
Open tool →Retention Path
Join the Linaclotide tracker waitlist
Capture refill timing, weekly dose history, and symptom notes in one planned workflow.
View tracker landing →Trust Summary
Reviewed 2026-04-27 by PeptideScholar editorial review. This page currently cites 2 official sources.
Pricing, savings eligibility, and coverage rules can change quickly. Verify all current figures and terms directly on official brand pages before acting.
Linaclotide Cost FAQ
Sources
- 1. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.Am J Gastroenterol • 2012Claim type: clinicalView source →
- 2. FDA Information on LinaclotideFDA • 2026Claim type: regulatoryView source →
This content is for informational purposes only and does not constitute medical advice.